Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Lucence
AddedFeb 15, 2024
UpdatedJun 18, 2026
Lucence

Lucence

Series A

Lucence: Precision oncology firm offering ultrasensitive liquid biopsy tests for early cancer detection.

HQ
Palo Alto, CA, US
Founded
2016
Overview
Compare
Fundraising
Employees
Website

Lucence, a precision oncology company, was founded with the mission to bring clarity to cancer care through innovative diagnostics. The company specializes in developing ultrasensitive non-invasive liquid biopsy tests, which provide crucial information for the early detection and effective treatment of cancer. Lucence aims to redefine the future of early cancer detection by creating advanced blood-testing technologies that are both accurate and affordable, targeting a global market of healthcare providers and patients.

Notable figures affiliated with Lucence include its founder and key investors who have supported its growth. The company has achieved significant milestones, including the development and commercialization of its LiquidHALLMARK® multi-cancer screening test. Lucence's work has had a profound impact on the field of oncology, offering new hope for earlier cancer diagnosis and improved patient outcomes.

Lucence - Similar Companies

Liquid Biotech logo

Liquid Biotech

Foresight Diagnostics logo

Foresight Diagnostics

foresight-dx.com

Salish Bioscience logo

Salish Bioscience

AccuraGen logo

AccuraGen

Pharus Diagnostics logo

Pharus Diagnostics

pharusdx.com

Liquid Genomics logo

Liquid Genomics

Exai Bio logo

Exai Bio

exai.bio

Thrive Earlier Detection logo

Thrive Earlier Detection

Circulogene Theranostics logo

Circulogene Theranostics

circulogene.com

Micronoma logo

Micronoma

micronoma.com

Torpedo Diagnostics logo

Torpedo Diagnostics

Lucid Diagnostics logo

Lucid Diagnostics

luciddx.com

Harbinger Health logo

Harbinger Health

Early Detection logo

Early Detection

cancer.us

Hawkeye Bio logo

Hawkeye Bio

hawkeyebio.com

Lucence - Quick Facts

Who are Lucence's competitors?

Companies similar to Lucence include Liquid Biotech, Foresight Diagnostics, Salish Bioscience and AccuraGen.

When was Lucence founded?

Lucence was founded in 2016.

Where is Lucence's headquarters located?

Lucence's headquarters is located in Palo Alto, CA, US.

When was Lucence's last funding round?

Lucence's most recent funding round was for $20M (USD) in November 2019.

How much has Lucence raised to-date?

As of Nov 20, 2019, Lucence has raised a total of $29.2M (USD).

How many employees does Lucence have?

Lucence has 85 employees as of Feb 4, 2024.

Lucence - Classification

Ownership
  • Private
Technology
  • Biotech
Geographic Exposure
  • Global
Revenue
  • Recurring
  • Software
Customer
  • Enterprise
Main Product
  • Liquid Biopsy
Tags
  • Healthtech
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541500Computer Systems Design and Related Services
  • 541000Professional, Scientific, and Technical Services
  • 541510Computer Systems Design and Related Services
  • 541511Custom Computer Programming Services
SIC
  • 7300Business Services
  • 7370Computer Programming, Data Processing, And Other Computer Related
  • 7371Computer Programming Services
Show 9 more industry codes
NAICS
  • 513200Software Publishers
  • 510000Information
  • 620000Health Care and Social Assistance
  • 513000Publishing Industries
  • 513210Software Publishers
SIC
  • 8000Health Services
  • 8040Offices And Clinics Of Other Health Practitioners
  • 7372Prepackaged Software
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified